Company intelligence / Profile preview

Emblem Technology Partners

Heidelberg, Germany

Ownership: Private
Development stage: Other

Overview

EMBLEM is the technology transfer and commercialization arm of the European Molecular Biology Laboratory. It manages a portfolio exceeding 1,000 inventions, over 450 patent applications and granted patents, and more than 400 active license contracts. The organization has returned over €40 million in annual surplus to EMBL over 20 years and generated €10 million+ annually from licensing, collaboration, service and consultancy contracts.

Modalities: small moleculesmonoclonal antibodiesbiologics
Industry: Drug Discovery Services

Partnerships

EMBL VenturesLife Sciences PartnersOpen Targets (with Wellcome Trust and pharma partners)MRC Technology

Beyond the preview

Go deeper on Emblem Technology Partners.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Emblem Technology Partners.

Explore the full profile